Overview

A Study of the IGF-1R Inhibitor AXL1717 in Combination With Gemcitabine HCL and Carboplatin to Treat Non-small-cell Lung Cancer (NSCLC)

Status:
Completed

Trial end date:
2012-09-01

Target enrollment:

Participant gender:

Summary

This is a open single-center, explorative, Phase I pilot dose finding study including patients treated with AXL1717 in addition to standard chemotherapy of gemcitabine HCL and carboplatin.

Phase:

Phase 1

Details

Lead Sponsor:

Axelar AB

Treatments:

Carboplatin
Gemcitabine